WuXi Biologics increases issued shares through option exercises

WuXi Biologics (Cayman) Inc. reported an increase in its total issued shares by 3,112,000, bringing the new total to 4,105,770,633 ordinary shares as of November 18, 2025. This change primarily stems from the exercise of share options and awards under the company’s Pre-IPO Share Option Scheme, adopted on January 5, 2016.

The company issued 52,000 new shares to participants (excluding directors) at an issue price of HK$1.29 per share, representing a 0.00127% increase. An additional 60,000 new shares were issued under the same scheme to participants (excluding directors) at HK$1.29 per share, accounting for a 0.00146% increase. Furthermore, 3,000,000 new ordinary shares were issued to a director of the issuer at HK$1.29 per share, contributing a 0.07312% rise in issued shares.

The disclosures confirm that all monies due have been received, pre-conditions for listing fulfilled, and all issued securities are identical. The company has also assured compliance with all legal and regulatory requirements concerning these share issuances.